143 results on '"Di Bona, E"'
Search Results
2. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet
3. Corrigendum: 'Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience' (Leukemia Research (2022) 114, (106803), (S0145212622000297), (10.1016/j.leukres.2022.106803))
4. Corrigendum to 'Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience' [Leukemia Res. 114 (March 2022) 106803](S0145212622000297)(10.1016/j.leukres.2022.106803)
5. VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL
6. Genomic gain at 6p21: a new cryptic molecular rearrangement in secondary myelodysplastic syndrome and acute myeloid leukemia
7. NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey
8. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation
9. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy
10. ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY
11. CLINICAL SIGNIFICANCE OF END OF INDUCTION MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN COMPLETE REMISSION AFTER A SINGLE CHEMOTHERAPY COURSE
12. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation
13. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia
14. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
15. IMPACT OF KIT MUTATIONS IN ACUTE MYELOID LEUKAEMIA WITH INV(16)
16. Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with INV(16)
17. Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy: Report of a second case
18. SIMILAR BUT NOT THE SAME: CHROMOSOMAL ABNORMALITIES T(8;21)(Q22;Q22) AND INV(16)(P13;Q22)/T(16;16)(P13;Q22) IDENTIFY SUBTYPES OF CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA CHARACTERIZED BY DIFFERENT SURVIVAL AND PROGNOS- TIC FACTORS
19. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
20. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
21. Management of paroxysmal nocturnal haemoglobinuria in the eculizumab era: the bedside and beyond
22. P1725: OBSERVATIONAL STUDY TO EVALUATE PATIENT‐REPORTED OUTCOMES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.
23. Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy
24. The Italian Way of Treating Acute Promyelocytic Leukemia (APL), Final Act
25. Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo AML
26. AIDA: The italian way of treating acute promyelocytic leukemia (APL): final act
27. Common Polymorphisms in the Metabolic Folate Pathway Decrease the Risk of Acute Lymphocitic Leukemia in Adults
28. Common Gene Polymorphisms in the Metabolic Folate and Methylation Pathway and the Risk of Acute Lymphoblastic Leukemia and non-Hodgkin’s Lymphoma
29. Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo cases
30. Common Polymorphisms in the Metabolic Folate Pathway Decrease the Risk of Acute Lymphocytic Leukemia in Adults
31. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Italian Aplastic Anaemia Study Group
32. Antilymphocyte globulin, cyclosporine, prednisone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients
33. Characterization of 12p molecular events outside ETV6 in complex karyotypes of acute myeloid malignancies
34. OC-09 New potential markers of severe thrombo-hemorrhagic syndrome (THS) in acute promyelocytic leukemia (APL) patients: activated FVII-antithrombin complex (FVIIa-AT) and Tissue Factor (TF) mRNA
35. Acquired haemophilia: experience of two Italian centres with 17 new cases.
36. Therapy-Related Myelodysplastic Syndrome (sMDS) /Acute Myelogenous Leukemia (sAML) in Acute Promyelocytic Leukemia (APL) Patients with Long-Lasting Molecular Remission: The GIMEMA Experience.
37. Incidence of coronary artery disease in patients with valvular heart disease
38. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
39. Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy
40. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study
41. Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
42. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia.
43. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
44. Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR
45. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
46. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
47. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
48. Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with inv(16). A retrospective study
49. Gemtuzumab Ozogamicin (Mylotarg) as a single agent for moleculary relapsed acute promyelocytic leukemia
50. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.